Jeffrey VanDeusen
Overview
Explore the profile of Jeffrey VanDeusen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
117
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Villalona-Calero M, Tian L, Li X, Palmer J, Aceves C, Meisen H, et al.
JCI Insight
. 2025 Feb;
PMID: 39903538
Background: Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality necessitating the exploration of alternate therapeutic approaches. Tumor reactive or activated-by-cytokine killers (TRACK) are PD-L1+ highly cytolytic...
2.
Rinehardt H, Kassem M, Morgan E, Palettas M, Stephens J, Suresh A, et al.
Eur J Breast Health
. 2021 Oct;
17(4):371-377.
PMID: 34651117
Objective: Leptomeningeal carcinomatosis (LMC), a common complication of advanced malignancies, is associated with high morbidity and mortality, yet diagnosis and treatment decisions remain challenging. This study describes the diagnostic and...
3.
Zhang Y, Asad S, Weber Z, Tallman D, Nock W, Wyse M, et al.
BMC Cancer
. 2021 May;
21(1):568.
PMID: 34006255
Background: Triple-negative breast cancer (TNBC) is a heterogeneous disease and we have previously shown that rapid relapse of TNBC is associated with distinct sociodemographic features. We hypothesized that rapid versus...
4.
Amigo M, Hoffman K, Chung C, Lustberg M, Wesolowski R, VanDeusen J, et al.
J Am Acad Dermatol
. 2021 May;
86(6):1346-1348.
PMID: 33961922
No abstract available.
5.
Nymberg K, Folan S, Berger M, Li J, Zanath K, VanDeusen J, et al.
Support Care Cancer
. 2021 Jan;
29(8):4423-4429.
PMID: 33447864
Purpose: The purpose of this study was to compare the incidence of rescue medication utilization with up to 3 subsequent doses of paclitaxel in patients who underwent an infusion rate...
6.
Sardesai S, Sukumar J, Kassem M, Palettas M, Stephens J, Morgan E, et al.
Cardiooncology
. 2020 Dec;
6(1):26.
PMID: 33292843
Background: Trastuzumab-induced cardiotoxicity (TIC) can lead to early discontinuation of adjuvant therapy, however there is limited evidence on long-term survival outcomes in patients with operable human epidermal growth factor receptor...
7.
Stover D, Reinbolt R, Adams E, Asad S, Tolliver K, Abdel-Rasoul M, et al.
JCO Precis Oncol
. 2020 Sep;
3.
PMID: 32923860
Purpose: To evaluate the impact of targeted DNA sequencing on selection of cancer therapy for patients with metastatic breast cancer (MBC). Patients And Methods: In this prospective, single-center, single-arm trial,...
8.
Liu J, Suresh A, Palettas M, Stephens J, Ganju A, Morgan E, et al.
Eur J Breast Health
. 2020 Jul;
16(3):201-207.
PMID: 32656521
Objective: The primary objective of this study was to delineate differences in management, overall and distant disease-free survival in males diagnosed with breast cancer and treated at The Ohio State...
9.
Wesolowski R, Stiff A, Quiroga D, McQuinn C, Li Z, Nitta H, et al.
BMC Cancer
. 2020 May;
20(1):445.
PMID: 32429929
Background: While combinations of immune checkpoint (ICP) inhibitors and neo-adjuvant chemotherapy (NAC) have begun testing in patients with breast cancer (BC), the effects of chemotherapy on ICP expression in circulating...
10.
Boutrid H, Kassem M, Tozbikian G, Morgan E, White J, Shah M, et al.
Front Endocrinol (Lausanne)
. 2020 May;
11:228.
PMID: 32411090
Primary small cell carcinoma of the breast (SCCB) is a rare tumor subtype comprising <0.1% of all breast carcinomas. Here we present a case of thyroid transcription factor-1 (TTF-1) positive...